Study the changes in levels of lipid profile and liver enzymes in type 2 DM

2022 ◽  
Author(s):  
Mustafa Abdulmajeed Hussein
Keyword(s):  
Lipid Profile ◽  
Liver Enzymes ◽  
Type 2 Dm

scholarly journals Correlation Between Lipid Profile with Type 2 Diabetes Mellitus Progression

2020 ◽  
Vol 8 (2) ◽  
pp. 66-72
Author(s):  
Angiesta Pinakesty ◽  
Restu Noor Azizah
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Lipid Profile ◽  
Cholesterol Levels ◽  
Type 2 Dm ◽  
Hba1c Levels

Introduction: Diabetes mellitus (DM) is a non-communicable disease that has increased from year to year. Type 2 diabetes mellitus is not caused by lack of insulin secretion, but is caused by the failure of the body's cells to respond to the hormone insulin (insulin resistance). Insulin resistance was found to be a major contributor to atherogenic dyslipidemia. Dyslipidemia in DM risks 2 to 4 times higher than non-DM. Although dyslipidemia has a great risk for people with type 2 diabetes mellitus, this conventional risk factor only explains a portion (25%) of excess cardiovascular risk in type 2 DM. Discussion: In uncontrolled type 2 DM patients, LDL oxidation occurs faster which results from an increase in chronic blood glucose levels. Glycemic control as a determinant of DM progressivity is determined through HbA1c examination. HbA1c levels are associated with blood triglyceride levels. Meanwhile, triglyceride levels are associated with total cholesterol and HDL cholesterol levels. HbA1c levels are also associated with LDL cholesterol levels. Conclusion: There is a relationship between lipid profile and the progression of type 2 diabetes mellitus.   Keywords: type 2 diabetes mellitus, dyslipidemia, HbA1c, glycemic control, lipid profile

scholarly journals An open randomized study to compare effect of metformin versus acarbose monotherapy on glycemic control and lipid profile in newly diagnosed type 2 diabetes mellitus patients

2021 ◽  
Vol 9 (3) ◽  
pp. 755
Author(s):  
Ram A. Manda ◽  
Veena Verma ◽  
Krishna Biswas
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Glycemic Control ◽  
Lipid Profile ◽  
Randomized Study ◽  
Initial Therapy ◽  
Newly Diagnosed ◽  
Type 2 Dm ◽  
Control Serum

Background: Type 2 DM is one global health problem and a main cause of morbidity and mortality. It is epidemic in many industrialized and developing areas and is considered to be one of the most challenging health problems of the 21st century. Metformin and acarbose both are used as monotherapy and in combination with other anti-diabetes drugs for treatment of type 2 DM. There are very sparse evidences regarding comparative efficacy and safety of metformin versus acarbose, especially in Asian region. In addition to glycemic control, improvement in lipid profile, weight loss and post-prandial sugar level are important therapeutic objectives for better management of type 2 DM patients.Methods: In this study, 60 newly diagnosed type 2 DM were randomly assigned (1:1) to oral acarbose (titrated doses upto 300 mg daily) or oral metformin (titrated doses up to 2500 mg daily) monotherapy and were followed-up for 12 weeks for effects on glycaemic control [serum HbA1C, fasting blood sugar and post prandial sugar and serum LDL, HDL, triglycerides and total cholesterol.Results: Reduction in FBS, HbA1C and body weight was found significantly greater with metformin while acarbose yielded greater improvement in PPS, total cholesterol and triglyceride levels. Both metformin and acarbose yielded significant improvement in FBS, PPS, HbA1C, lipid profile and body weight after 12 weeks of therapy and yielded similar improvement in LDL and HDL levels.Conclusions: Acarbose can be considered as an alternative initial therapy in newly diagnosed type 2 diabetes patients, particularly those with isolated post-prandial hyperglycemia and those who are intolerant to metformin therapy. 

scholarly journals Synergistic effect of metformin and fenugreek on the lipid profile of type-II diabetic patients

2019 ◽  
Vol 8 (8) ◽  
pp. 1738
Author(s):  
Manmeet Kaur ◽  
Narinder Singh
Keyword(s):  
Lipid Profile ◽  
Diabetic Patients ◽  
Hypolipidemic Effect ◽  
Fenugreek Seeds ◽  
Beneficial Effects ◽  
Type 2 Dm ◽  
Group 2 ◽  
Student’S T ◽  
Group 1

Background: Fenugreek is a traditional herb which has great relevance in the world since time immemorial due to its multifarious uses. Besides being a rich source of nutrition, it also finds place in the cure of certain pathological conditions. One of its highly beneficial effects is have been observed on the lipid profile of the hyperlipidemic patient. This study was thus undertaken to see the hypolipidemic effect of fenugreek seeds in patients of Type 2 Diabetes Mellitus (DM) as add-on therapy with metformin.Methods: An open-labelled comparative study of 12 weeks duration was conducted on patients (randomly divided in 2 groups of 30 each) of Type 2 DM. Group 1 was given metformin 500 mg twice a day while group 2 was given 500 mg of metformin along with fenugreek seed powder capsule, 1gm thrice a day. Evaluation for fasting lipid profile estimation was done at the beginning and at the end of the study. Student’s t-test (paired and unpaired) was applied for statistical analysis.Results: After 12 weeks of treatment, there was significant improvement in the lipid profile of both the groups. However, group 2, that received fenugreek along with metformin showed statistically greater improvement as compared to group 1 which received only metformin.Conclusions: This study shows the beneficial effects of fenugreek seeds on lipid profile in patients of Type 2 DM and can be used as an add-on therapy with metformin in controlling the lipid profile of Type 2 DM.

scholarly journals Effectiveness of atorvastatin therapy in patients with arterial hypertension, diabetic nephropathy and diabetes mellitus type 2

2019 ◽  
pp. 105-110
Author(s):  
O. M. Chernatska ◽  
T. S. Mazur ◽  
N. V. Demikhova ◽  
O. M. Vlasenko ◽  
T. M. Rudenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Nephropathy ◽  
Arterial Hypertension ◽  
Lipid Profile ◽  
Cardiovascular Complications ◽  
Actual Problem ◽  
Type 2 Dm

The actual problem of internal medicine is the managemen of patients with comorbid pathology. Arterial hypertension (AH) is determined in about quarter of the population in the world. Moreover, the coexistence of AH and type 2 diabetes mellitus (DM) connected with the increased risk of cardiovascular complications (CVC) compared with patients with AH. In principle dyslipidemia is the common link between AH and type 2 DM, which need the correction. No doubt that reduction of atherogenic and increase of anti atherogenic lipoproteins is necessary for persons with comorbid pathology. The objective of our study was the assessment of atorvastatin treatment in patients with AH, diabetic nephropathy and type 2 DM. We obtained 96 patients with AH, diabetic nephropathy and type 2 DM (І group), 25 persons with AH (ІІ group), 15 conditionally healthy individuals. Persons had CVC in the past. For patients from the І and ІІ group CVC were defined accordingly (4,97 ± 0,20) years and (4,10 ± 0,05) years ago (P = 0,0291). The duration of AH is (8,1 ± 0,2) years for the І group and (8,90 ± 0,13) years for the ІІ group. The levels of lipid profile spectrum were determined according to the methods of W. T. Friedewald. The results of investigation were analyzed with the help of Microsoft Excel 2016. Correction of lipid profile spectrum is the important part of multipurpose treatment for persons with coexistent pathology. All patients were treated by atorvastatin (10−40 mg/day) during 6 months in a complex therapy. The target levels of general cholesterol during 6 months were presented in 30 persons (31.91 %), low density lipoproteids – in 10 persons (10.64 %), high density lipoproteids – in 26 persons (27.66 %), triglycerides – in 34 persons (36.17 %) among patients with AH, diabetic nephropathy and type 2 DM. In conclusion, it is advisable to prescribe atorvastatin (10–40 mg/day) for correction of dyslipidemia, reduction of proatherogenic orientation, prevention of atherosclerotic process manifestation and cardiovascular complications in patients with AH with diabetic nephropathy and type 2 diabetes mellitus.

scholarly journals Lipid Profile Pattern in Type 2 Diabetes Mellitus Patients

2020 ◽  
Vol 14 (2) ◽  
pp. 177-179
Author(s):  
Most Sarmin Sultana ◽  
Yasmin Akhter ◽  
Mimi Parvin ◽  
Md Mahbub Ul Alam ◽  
Lubna Naznin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Lipid Profile ◽  
Density Lipoprotein ◽  
Armed Forces ◽  
Lipoprotein Cholesterol ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Dm ◽  
Type 2 Diabetic

Introduction: Dyslipidemia has been noted to play an integral role in the pathogenesis and progression of micro and macrovascular complications in Diabetes Mellitus (DM) patients. Lipid profile is the indicators of dyslipidemia. Objectives: To evaluate the prevalence and pattern of dyslipidemia in type 2 DM patients. Materials and Methods: This cross sectional study was conducted at Armed Forces Institute of Pathology (AFIP) from November 2014 to October 2015. The study included 300 type 2 diabetic patients belonging to the age group 30-59 years. Personal data and history of co-existing medical conditions were collected by data collection sheet and analyzed. Results: Among 300 study subjects with type 2 DM the prevalence of dyslipidemia was 94% among them 19% had single dyslipidemia and 75% had multiple dyslipidemia. In this study, high level of total cholesterol (TC), triglycerides(TG) and Low Density Lipoprotein-Cholesterol (LDL-C) were found in 47.3%, 76.7% and 41.3% patients respectively. High Density Lipoprotein- Cholesterol (HDL-C) levels were found to be low in 60% patients. Conclusion: The study revealed that dyslipidemia is very common in type 2 diabetic patients and the most common abnormality observed was increased serum TG level followed by decreased HDL-C level. So, patients with type 2 DM should be followed up with serum lipid profile regularly. Journal of Armed Forces Medical College Bangladesh Vol.14 (2) 2018: 177-179

scholarly journals ECHO OF LODHRADI KASHAYA IN LIPID PROFILE OF TYPE 2 DIABETES MELLITUS PATIENTS

2017 ◽  
Vol 10 (5) ◽  
pp. 309
Author(s):  
Varun Kumar Singh ◽  
Krc Reddy
Keyword(s):  
Diabetes Mellitus ◽  
Lipid Profile ◽  
Treatment Approach ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Diabetic Mellitus ◽  
Type 2 Dm ◽  
High Lipid ◽  
Central Council

Objective: Lipid profile is matter to concern in fast changing lifestyle, and especially in diabetic mellitus (DM) patients. In arena of DM, obesity and high lipid contour is a causative problem and lead to generate the related problems too. Hence, tracking of lipid profile in DM patients is necessary as part of treatment approach. Hence, the present study was conducted to track the effect of Lodhradi Kashaya spray dried (LKSD) powder on lipid profile in Type 2 DM patients.Methods: Total 31 patients were taken following the guideline mention in Central Council for Research in Ayurveda and Siddha protocol for DM research. They were divided into two groups, Groups A and B and given LKSD (4 and 2 g TDS (three times a day), respectively, dissolved in water) for 3 months. They are investigated for their blood serum creatinine and lipid profile (cholesterol, low-density lipoprotein [LDL], high-density lipoprotein [HDL], very LDL [VLDL], and triglyceride). The patients response has also been noted regarding palatability acceptance and ease of administration.  Result: LKSD was found significantly effective in total cholesterol (p=0.001 and 0.073), triglyceride (p=0.002 and 0.003), HDL (p˂0.001 and 0.026), LDL (p=0.563 and p˂0.001), and VLDL (p=0.024 and 0.003). Patients had reported that formulation is easy to take in spite of its astringency in taste.Conclusion: Lodhradi Kashaya has capability to control and take care of disturbance in lipid profile in DM patients and thus enhance their living confidence.Keywords: Ayurveda, Lodhradi Kashaya, Diabetes mellitus, Clinical study, Lipid profile.

Sign in / Sign up

Export Citation Format

Share Document